Sen. Jeanne Shaheen

Maddy summaryThe SAFE Chips Act of 2025 requires U.S. exporters to obtain government licenses before sending advanced computer chips to "foreign adversary countries" (including China, Hong Kong, and Macau) or to entities owned by such countries. It defines "advanced integrated circuits" using specific technical standards, such as high processing power (e.g., 4,800+ performance points) or bandwidth (e.g., 4,100+ gigabytes per second), excluding chips designed for data centers. The bill mandates license denials for these exports and allows the Commerce Secretary to update technical definitions after 30 months, with required Congressional briefings on national security impacts. This directly affects chip manufacturers and companies exporting to specified regions, imposing strict controls on advanced semiconductor trade.

Maddy summaryThis Senate resolution (SRES 525) condemns the Iranian government's ongoing, state-sponsored persecution of the Baha'i minority, citing decades of systemic abuses including executions, job dismissals, education bans, and property confiscations. It references UN reports and Human Rights Watch findings documenting Iran's violation of international human rights treaties, such as the Universal Declaration of Human Rights and the International Covenant on Civil and Political Rights. The resolution calls on Iran to immediately release imprisoned Baha'is, end discriminatory policies restricting their education and employment, and cease hate propaganda, while urging the U.S. President and Secretary of State to impose sanctions on Iranian officials responsible for these abuses.

Maddy summaryThe LAB Personnel Act of 2025 (S 3334) protects the laboratory workforce at the Drug Enforcement Administration (DEA) from hiring freezes or workforce reductions caused by budget cuts or fund reprogramming. It directly affects DEA forensic lab staff, including forensic chemists, fingerprint specialists, digital forensic examiners, and other defined roles in DEA forensic laboratories. The bill mandates that these positions be exempt from reductions related to spending constraints, while clarifying that it does not prevent the Attorney General from managing staff under existing misconduct or performance procedures. This is a concrete policy change to maintain staffing levels in DEA forensic operations.

Maddy summaryThis concurrent resolution (SCONRES 24) commemorates the 30th anniversary of the Dayton Peace Accords, signed on December 14, 1995, which ended the Bosnian War. It recognizes the accords' role in halting conflict, ending ethnic cleansing, and establishing peace in Bosnia and Herzegovina, while highlighting Dayton, Ohio's historical role in hosting the negotiations. The resolution reaffirms U.S. support for Bosnia and Herzegovina's sovereignty, EU/NATO partnership, and constitutional reforms, but contains no new laws or direct impacts on any group. As a ceremonial resolution, it does not alter policy or affect any individuals or entities.

Maddy summaryS 3302, the Mikaela Naylon Give Kids a Chance Act of 2025, requires drug manufacturers developing cancer treatments to conduct pediatric-focused research for certain drugs targeting pediatric cancer mechanisms. It amends FDA drug approval processes to mandate molecularly targeted pediatric cancer investigations for drugs with new active ingredients or specific approved combinations, ensuring studies address dosing, safety, and efficacy for children. The bill also extends priority review vouchers (which expedite FDA reviews) for rare pediatric disease treatments until 2030 and mandates GAO studies to evaluate how effectively these incentives spur new pediatric cancer drug development. These changes apply to new drug applications submitted three years after the law's enactment, with reports due to Congress at 6, 8, and 10 years.

Maddy summaryThis bill requires the Secretaries of Defense and Veterans Affairs to evaluate existing research on menopause, perimenopause, and mid-life health for women serving in the military or who are veterans. It directs them to identify gaps in knowledge about treatments for symptoms, the impact of military service (including combat exposure and toxins like PFAS), and the availability of care and training for healthcare providers. Within 180 days of enactment, the departments must submit a report and strategic plan to Congress detailing findings and outlining steps to address research gaps and improve care. The law directly affects military women, veterans, and their healthcare providers by aiming to enhance understanding and services for menopause-related health issues.

Maddy summaryThis resolution designates November 2025 as "American Diabetes Month" in the U.S. Senate. It does not create new policies, funding, or programs - it is a symbolic designation to raise public awareness about diabetes. The resolution highlights diabetes statistics and health disparities but focuses solely on promoting education, prevention, and early detection efforts during that month. It has no direct impact on legislation, healthcare access, or costs.

Maddy summaryThe Healthy MOM Act (S 3274) would require health insurance plans to provide a special enrollment period for pregnant individuals beginning when pregnancy is reported to the insurer. It mandates that group health plans cover maternity care for dependents regardless of age, including labor and delivery, and extends Medicaid eligibility during pregnancy and postpartum. The bill requires 12 months of continuous coverage for pregnant and postpartum individuals under Medicaid and CHIP, replacing the current 60-day postpartum coverage period. These provisions aim to improve access to maternity care for women, particularly those from communities disproportionately affected by maternal mortality, such as Black and American Indian/Alaska Native women. The changes would apply to plan years beginning January 1, 2027, with some provisions having earlier effective dates for certain programs.

Maddy summaryS 3267, the ASAP Act, would require Medicare to cover early detection screening tests for Alzheimer's disease and related dementias starting January 1, 2028. The bill defines these tests as FDA-cleared or approved blood, genomic, or imaging-based screenings for pre-symptomatic or early-stage detection. It directly affects Medicare beneficiaries aged 65+ who may be at risk for Alzheimer's, ensuring coverage for these specific tests once approved. The key provision adds these screenings to Medicare's payment system under Section 1833(h)(1)(A) of the Social Security Act.

Maddy summaryThe SIMSA Act of 2025 creates a new Schedule A for controlled substances under federal drug law. It defines Schedule A substances as those imported into the U.S. with chemical structures substantially similar to existing Schedule I-V substances and having similar effects on the central nervous system. The bill establishes procedures for the Attorney General to temporarily schedule substances for up to 5 years (with possible 180-day extensions), requiring consultation with the Secretary of Health and Human Services before permanent scheduling. It increases penalties for violations involving Schedule A substances, including prison terms up to 30 years for repeat offenses and higher fines, and requires specific labeling with IUPAC nomenclature for these substances.